VATE INNOVATE CORP

INNOVATE Corp. Announces Date Change for Second Quarter 2023 Earnings Call

INNOVATE Corp. Announces Date Change for Second Quarter 2023 Earnings Call

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”), today announced a change to its second quarter 2023 earnings results and conference call date. The Company will now report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.

Updated Conference Call Details

Live Call

Domestic Dial-In: 1-888-886-7786

Toll/International: 1-416-764-8658

Conference Number: 85848080

Conference Replay*

Domestic Dial-In: 1-844-512-2921

Toll/International: 1-412-317-6671

Conference Number: 85848080

*Available approximately three hours after the end of the conference call through August 23, 2023.

About INNOVATE

INNOVATE Corp. is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,800 people across its subsidiaries. For more information, please visit: .

Contacts

Media Contact:

Reevemark

Paul Caminiti/Pam Greene/Luc Herbowy



(212) 433-4600

Investor Contact:

Solebury Strategic Communications

Anthony Rozmus



(212) 235-2691



EN
28/07/2023

Underlying

VATEINNOVATE CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INNOVATE CORP

 PRESS RELEASE
Free
VATE INNOVATE CORP

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mar...

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that  (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, announced receipt of European Union (EU) CE Mark certification under the EU Medical Device Regulation (MDR) for its TGFR™ Monitor and TGFR™ Reusable Sensor. The certificati...

March 31, 2026 1 EN
 PRESS RELEASE
Free
VATE INNOVATE CORP

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results - Infrastructure: NYC and Western markets continue to demonstrate positive project momentum -- Life Sciences: R2 Secures 600‑System Commitment in China -- Spectrum: Recent network launches set to deliver benefits beginning in 2026 - NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and full year ended December 31, 2025. Financial Summary (in millions, except per share amounts)Three Months Ended December 3...

March 26, 2026 1 EN
 PRESS RELEASE
Free
VATE INNOVATE CORP

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on ...

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2025 on Thursday, March 26, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be...

March 16, 2026 1 EN
 PRESS RELEASE
Free
VATE INNOVATE CORP

Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice...

Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN) MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal det...

February 10, 2026 1 EN
 PRESS RELEASE
Free
VATE INNOVATE CORP

INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend

INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5 million, or $1.30 per share, on February 24, 2026 to DBMG’s stockholders of record at the close of business on February 9, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $4.6 million o...

February 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch